Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?

scientific article published on 20 June 2010

Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1093/ANNONC/MDQ304
P8608Fatcat IDrelease_oufhemodb5bk7jw4w3xsxaqqmq
P698PubMed publication ID20566473
P5875ResearchGate publication ID44690982

P2093author name stringB Thürlimann
M Joerger
J Huober
P2860cites workTrastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialQ43241014
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerQ43250044
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerQ43270036
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trialQ46736552
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapiesQ47402211
Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategyQ47587986
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Q53243856
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerQ24641848
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Q24657145
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerQ27824847
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerQ29616112
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerQ34496969
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerQ36678853
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.Q37123529
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?Q43231278
P433issue1
P921main subjectbreast cancerQ128581
P1104number of pages7
P304page(s)17-23
P577publication date2010-06-20
P1433published inAnnals of OncologyQ326122
P1476titleSmall HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
P478volume22

Reverse relations

cites work (P2860)
Q46842669Does comparative effectiveness research promote rationing of cancer care?
Q35947005Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
Q35653774Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?
Q37595263HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.
Q38041467Management of small HER2 overexpressing tumours
Q34400615Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer
Q42571051Targeted therapy in HER2-positive breast cancer
Q91834210The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
Q51673307The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
Q38973381Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

Search more.